Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iradimed Corp (IRMD)
NASDAQ:IRMD
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.41Last Year’s EPS
0.36Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: -7.01%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with record-breaking revenue and growth, strong domestic sales, and increased earnings per share, despite challenges in international sales, a slight decline in gross margin, and impacts from capital expenditures.Company Guidance
During the IRADIMED CORPORATION Fourth Quarter 2024 Financial Results Conference Call, guidance was provided for the upcoming fiscal quarters. For Q1 2025, the company anticipates revenue between $19.2 million and $19.4 million, with GAAP diluted earnings per share ranging from $0.35 to $0.39, and non-GAAP diluted earnings per share expected to be between $0.39 and $0.43. For the full year 2025, IRADIMED projects revenue to fall between $78 million and $82 million, with GAAP diluted earnings per share of $1.55 to $1.65 and non-GAAP diluted earnings per share of $1.71 to $1.81. The company is also preparing for the launch of its new 3870 MR IV pump, expected to receive FDA clearance by mid-2025, with significant revenue from this device projected for 2026. Additionally, they are managing the construction of a new facility, expected to be completed by June 2025, which will aid in supporting future growth.Record-Breaking Revenue and Growth
IRADIMED CORPORATION reported its 14th consecutive record quarter with revenue exceeding $19.4 million, an increase of 11% compared to Q4 2023. Annual revenue for fiscal year 2024 increased by 12% to $73.2 million, driven by strong demand for IV pumps.
Strong Domestic Sales Performance
Domestic sales saw a significant increase of 21% to $16.5 million, accounting for approximately 85% of total revenue for Q4 2024, compared to 78% in the previous year.
Increased Earnings Per Share
GAAP diluted earnings per share increased by 11% from Q4 2023, and non-GAAP adjusted net income per diluted share increased by 12% year-over-year.
Successful Cost Management
Cash from operations increased to $6 million for Q4 2024, up from $3.9 million in the previous year, due to efficient working capital management.
---
IRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $60.48 | $55.40 | -8.40% |
| Oct 31, 2024 | $52.79 | $49.13 | -6.93% |
| Aug 01, 2024 | $46.42 | $45.87 | -1.18% |
| May 02, 2024 | $41.60 | $43.43 | +4.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Iradimed Corp (IRMD) report earnings?
Iradimed Corp (IRMD) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Iradimed Corp (IRMD) earnings time?
Iradimed Corp (IRMD) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRMD EPS forecast?
IRMD EPS forecast for the fiscal quarter 2025 (Q1) is 0.41.
---